DAFTAR PUSTAKA
1. (Smeltzer, S C and Bare, B.G, 2002 : 248 ) 2. Dipiro, J,T., et al, 2008, Pharmacoterapy Handbook, seven edition, Mc Graw Hill. 3. A.V.Hoffbrand,, dkk.2005. Kapita Selekta Hematologi. Edisi 4. Penerbit Buku Kedokteran EGC.Jakarta 4. Robbins dan Cotran (2009). Buku Saku Dasar Patologis Penyakit (ed.7) Kapita Selekta Hematologi .Jakarta: EGC 5. Manley, P.W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T. and Zimmermann, J. (2002). "Imatinib: a selective tyrosine kinase inhibitor". European Journal of Cancer: S19-S27. 6. Matsumoto K, Hories S, Ishikawa H,etal (2004). Antinociceptive effect of 7hydroxymitragynine in mice: discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Science, 74, 2143-55. 7. Nelson JL, Lapoint J, Hodgman MJ, etal (2010). Seizure and coma following kratom (mitragynina speciosa korth) Exposure. J Med Toxicol, 6, 424-6. 8. Gupta SK, Selvan VK, Agrawal SS, et al (2009). Advances in pharmacologica lstrategies for the prevention of cataract development. Indian J Ophthalmol,57, 175-83. 9. Teik Beng Goh1 Mohd Nizam Mordi 10. Leach et al. (2006)
11. Bakta, I.M. 2007. Hematologi Klinik Ringkas, Jakarta:EGC 12. Colby-Graham, M. and Chordas, C.( 2003) The childhood leukaemia’s. Journal of Pediatric Nursing 18 (2),87-95 13. (Bain, Gupta, 2003). 14. Novindriana D.2013. Uji efek sedative fraksi etanol daun kratom (Mitragyna Speciosa. korth) pada mencit jantan galur BALB/c. [Skripsi]. Farmasi Fakultas Kedokteran:Universitas Tanjungpura Pontianak (ID). 15. Vapjayee.2011
1. Jump up^ Nowell, Peter; Hungerford, David (1960). "A minute chromosome in human chronic granulocytic leukaemia.". Science. 132: 1497. 2. ^ Jump up to:a b c d e f g h i j k An, X.; Tiwari, A.; Sun, Y.; Ding, P.; Ashby Jr, C.; Chen, Z. (2010). "BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review". Leukemia research. 34 (10): 1255–1268. doi:10.1016/j.leukres.2010.04.016. PMID 20537386. 3. ^ Jump up to:a b c d e f g Bixby, D., Talpaz, M. (2009). "Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance". Hematology: 461-476. 4. ^ Jump up to:a b c Manley, P.W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T. and Zimmermann, J. (2002). "Imatinib: a selective tyrosine kinase inhibitor". European Journal of Cancer: S19-S27. 5. Jump up^ Shawver, L. K., Slamon, D. and Ullrich, A. (2002). "Smart drugs:Tyrosine kinase inhibitors in cancer therapy". Cancer Cell: 117-123.
6. ^ Jump up to:a b Druker, B. J. and Lydon, N. B. (2000). "Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia". The journal of Clinical Investigation: 3-7. 7. ^ Jump up to:a b Buchanan, S. G. (2003) "Protein structure: discovering selective protein kinase inhibitors". Targets: 101-108. 8. ^ Jump up to:a b c d Eck, M.; Manley, P. (2009). "The interplay of structural information and functional studies in kinase drug design: insights from BCRAbl". Current opinion in cell biology. 21 (2): 288– 295. doi:10.1016/j.ceb.2009.01.014. PMID 19217274. 9. Jump up^ Mandal, S.; Moudgil, M.; Mandal, S. (2009). "Rational drug design". European Journal of Pharmacology. 625 (1–3): 90– 100. doi:10.1016/j.ejphar.2009.06.065. PMID 19835861. 10. ^ Jump up to:a b c d Asaki, T.; Sugiyama, Y.; Hamamoto, T.; Higashioka, M.; Umehara, M.; Naito, H.; Niwa, T. (2006). "Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors". Bioorganic & Medicinal Chemistry Letters. 16 (5): 1421– 1425. doi:10.1016/j.bmcl.2005.11.042. PMID 16332440. 11. ^ Jump up to:a b c d e f g h i j k l Manley, P.; Cowan-Jacob, S.; Mestan, J. (2005). "Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia". Biochimica et
Biophysica Acta. 1754 (1–2): 3– 13. doi:10.1016/j.bbapap.2005.07.040. PMID 16172030. 12. ^ Jump up to:a b c d e f g Manley, P.; Stiefl, N.; Cowan-Jacob, S.; Kaufman, S.; Mestan, J.; Wartmann, M.; Wiesmann, M.; Woodman, R.; Gallagher, N. (2010). "Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib". Bioorganic & Medicinal Chemistry. 18 (19): 6977– 6986. doi:10.1016/j.bmc.2010.08.026. PMID 20817538. 13. ^ Jump up to:a b Stein, B., Smith, B.D. (2010). "Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib". Clinical Therapeutics: 804-820. 14. Jump up^ Gorre, M.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. (2001). "Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification". Science: 876–880. 15. Jump up^ Thomas, J.; Wang, L.; Clark, R.; Pirmohamed, M. (2004). "Active transport of imatinib into and out of cells: implications for drug resistance". Blood. 104 (12): 3739–3745. doi:10.1182/blood-2003-124276. PMID 15315971. 16. ^ Jump up to:a b c d e f g h Jabbour, E.; Cortes, J.; Kantarjian, H. (2009). "Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review". Core evidence. 4: 207–213. PMC 2899790 . PMID 20694077.
17. ^ Jump up to:a b c d e f g h i Olivieri, A.; Manzione, L. (2007). "Dasatinib: a new step in molecular target therapy". Annals of Oncology. 18 Suppl 6: vi42– vi46. doi:10.1093/annonc/mdm223. PMID 17591830. 18. ^ Jump up to:a b c d Breccia, M.; Alimena, G. (2010). "Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia". Leukemia research. 34 (2): 129–134. doi:10.1016/j.leukres.2009.08.031. PMID 19783301. 19. Jump up^ Han, L.; Schuringa, J.; Mulder, A.; Vellenga, E. (2010). "Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases". Annals of Hematology. 89 (9): 861–871. doi:10.1007/s00277-0100948-7. PMC 2908401 . PMID 20387067. 20. Jump up^ Tokarski, J. S.; Newitt, J. A.; Chang, C. Y.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. (2006). "The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants". Cancer Research. 66 (11): 5790–5797. doi:10.1158/0008-5472.CAN-054187. PMID 16740718. 21. ^ Jump up to:a b c d Boschelli, F.; Arndt, K.; Gambacorti-Passerini, C. (2010). "Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia". European journal of cancer (Oxford, England : 1990). 46 (10): 1781– 1789. doi:10.1016/j.ejca.2010.02.032. PMID 20399641. 22. Jump up^ http://www.ariad.com
23. Jump up^ O'Hare, T.; Pollock, R.; Stoffregen, E. P.; Keats, J. A.; Abdullah, O. M.; Moseson, E. M.; Rivera, V. M.; Tang, H.; Metcalf Ca, C. A.; Bohacek, R. S.; Wang, Y.; Sundaramoorthi, R.; Shakespeare, W. C.; Dalgarno, D.; Clackson, T.; Sawyer, T. K.; Deininger, M. W.; Druker, B. J. (2004). "Inhibition of wild-type and mutant BcrAbl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML". Blood. 104 (8): 2532–2539. doi:10.1182/blood-2004-051851. PMID 15256422. 24. Jump up^ Huang, W.; Zhu, X.; Wang, Y.; Azam, M.; Wen, D.; Sundaramoorthi, R.; Thomas, R.; Liu, S.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Daley, G. Q.; Iuliucci, J.; Dalgarno, D. C.; Clackson, T.; Sawyer, T. K.; Shakespeare, W. C. (2009). "9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation". Journal of Medicinal Chemistry. 52 (15): 4743–4756. doi:10.1021/jm900166t. PMID 19572547. 25. Jump up^ Huang, W. S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D. (2010). "Discovery of 3-[2-(Imidazo[1,2b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant". Journal of Medicinal Chemistry. 53 (12): 4701– 19. doi:10.1021/jm100395q. PMID 20513156.
26. ^ Jump up to:a b O'Hare, T.; Shakespeare, W.; Zhu, X.; Eide, C.; Rivera, V.; Wang, F.; Adrian, L.; Zhou, T.; Huang, W.; Xu, Q.; Metcalf Ca, C. A.; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W. N.; Druker, B. J.; Clackson, T. (2009). "AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance". Cancer Cell. 16 (5): 401–412. doi:10.1016/j.ccr.2009.09.028. PMC 2804470 . PMID 19878872. 27. Jump up^ Kimura, S.; Naito, H.; Segawa, H.; Kuroda, J.; Yuasa, T.; Sato, K.; Yokota, A.; Kamitsuji, Y.; Kawata, E.; Ashihara, E.; Nakaya, Y.; Naruoka, H.; Wakayama, T.; Nasu, K.; Asaki, T.; Niwa, T.; Hirabayashi, K.; Maekawa, T. (2005). "NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia". Blood. 106 (12): 3948– 3954. doi:10.1182/blood-2005-06-2209. PMID 16105974. 28. Jump up^ Horio, T.; Hamasaki, T.; Inoue, T.; Wakayama, T.; Itou, S.; Naito, H.; Asaki, T.; Hayase, H.; Niwa, T. (2007). "Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives". Bioorganic & Medicinal Chemistry Letters. 17 (10): 2712– 2717. doi:10.1016/j.bmcl.2007.03.002. PMID 17376680.
29. Jump up^ Deguchi, Y.; Kimura, S.; Ashihara, E.; Niwa, T.; Hodohara, K.; Fujiyama, Y.; Maekawa, T. (2008). "Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines". Leukemia research. 32 (6): 980– 983. doi:10.1016/j.leukres.2007.11.008. PMID 18191450. 30. Jump up^ http://www.cytrx.com 31. ^ Jump up to:a b Radi, M.; Crespan, E.; Botta, G.; Falchi, F.; Maga, G.; Manetti, F.; Corradi, V.; Mancini, M.; Santucci, M.; Schenone, S.; Botta, M. (2008). "Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents". Bioorganic & Medicinal Chemistry Letters. 18 (3): 1207– 1211. doi:10.1016/j.bmcl.2007.11.112. PMID 18078752. 32. ^ Jump up to:a b Manetti, F.; Falchi, F.; Crespan, E.; Schenone, S.; Maga, G.; Botta, M. (2008). "N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds". Bioorganic & Medicinal Chemistry Letters. 18 (15): 4328– 4331. doi:10.1016/j.bmcl.2008.06.082. PMID 18621522. 33. Jump up^ Valent, P. (2010). "Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?". European Journal of Clinical Investigation. 40 (10): 918–931. doi:10.1111/j.13652362.2010.02328.x. PMID 20597967.
Bakta, I.M. 2007.
Hematologi Klinik Ringkas . Jakarta: EGC.Druker et.al. 2006. Five-Year Follow-up of Patients Receiving Imatinib forChronic Myeloid Leukemia . The New England Journal Medicine 2006 :355:2408-17.Hoffbrand, A.V., Pettit, J.E., Moss, P.A.H. 2005. Kapita Selekta Hematologi .Jakarta: EGCRobbins & Cotran., 2009. Buku Saku Dasar Patologis Penyakit (ed.7) . Jakarta:EGC.Bangun, Meidiana.2012. Analisis Faktor Kejadian Relapse Pada Anak Dengan Leukimia. Depok
